| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | METAP2 |
| Uniprot No | P50579 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-478aa |
| 氨基酸序列 | MAGVEEVAASGSHLNGDLDPDDREEGAASTAEEAAKKKRRKKKKSKGPSA AGEQEPDKESGASVDEVARQLERSALEDKERDEDDEDGDGDGDGATGKKK KKKKKKRGPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRT TSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKL EDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKI DFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDV GEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGG EATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTK HLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDI KGSYTAQFEHTILLRPTCKEVVSRGDDY |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于METAP2重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**: *"Cloning, Expression, and Characterization of Human Methionine Aminopeptidase 2 (METAP2) in Escherichia coli"*
**作者**: Lu J. et al.
**摘要**: 研究报道了人源METAP2基因在大肠杆菌中的重组表达与纯化，分析了其酶活性和金属离子依赖性，证实重组蛋白具有甲硫氨酸氨基肽酶活性，为后续抑制剂筛选奠定基础。
---
2. **文献名称**: *"Structural Basis for Inhibition of Methionine Aminopeptidase 2 by Fumagillin Analogues"*
**作者**: Griffith E.C. et al.
**摘要**: 通过X射线晶体学解析了METAP2重组蛋白与抑制剂(如TNP-470)的复合物结构，揭示了其催化机制及抑制剂结合位点，为抗血管生成药物设计提供结构依据。
---
3. **文献名称**: *"Recombinant METAP2 as a Therapeutic Target in Obesity: Enzymatic Activity and Small Molecule Inhibition Studies"*
**作者**: Kim Y.M. et al.
**摘要**: 探讨了重组METAP2在脂肪代谢中的作用，发现其抑制剂可调节能量平衡，在动物模型中减少脂肪积累，提示METAP2作为肥胖治疗靶点的潜力。
---
如需具体文献，建议通过PubMed或Sci-Hub输入标题/作者进一步检索全文。
METAP2 (methionine aminopeptidase 2) is a highly conserved cytosolic enzyme that plays a critical role in post-translational protein modification. It catalyzes the removal of initiator methionine residues from nascent polypeptides, a process essential for protein maturation, stability, and function. Specifically, METAP2 regulates the processing of proteins involved in cell proliferation, angiogenesis, and apoptosis by controlling the availability of N-terminal methionine-cleaved proteins. This metalloenzyme requires divalent cations (e.g., Co²⁺ or Mn²⁺) for catalytic activity and exhibits substrate specificity influenced by adjacent amino acids.
Recombinant METAP2 protein is produced through genetic engineering techniques, typically expressed in Escherichia coli or mammalian cell systems to ensure proper folding and enzymatic activity. Its recombinant form enables detailed structural studies (e.g., X-ray crystallography revealing its dinuclear metal center) and functional investigations into disease mechanisms. METAP2 gained therapeutic interest due to its overexpression in cancers and association with metabolic disorders. Notably, it was identified as a molecular target of anti-angiogenic compounds like fumagillin, spurring research into obesity and cancer therapies.
Pharmaceutical applications focus on developing METAP2 inhibitors to disrupt pathological angiogenesis or lipid metabolism. Recombinant METAP2 serves as a key tool for high-throughput drug screening, enzymology assays, and mechanistic studies of inhibitor binding. Recent research also explores its role in immune regulation and neurodegenerative diseases, expanding potential therapeutic relevance. Quality-controlled batches of recombinant METAP2 undergo rigorous characterization via SDS-PAGE, mass spectrometry, and activity assays to ensure batch-to-batch consistency for experimental and preclinical applications.
×
